Reviewing LivaNova (LIVN) & Alliqua Biomedical (ALQA)

LivaNova (NASDAQ: LIVN) and Alliqua Biomedical (NASDAQ:ALQA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Profitability

How to Become a New Pot Stock Millionaire

This table compares LivaNova and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova -2.10% 9.37% 6.84%
Alliqua Biomedical -131.40% -108.49% -61.88%

Analyst Recommendations

This is a breakdown of recent ratings for LivaNova and Alliqua Biomedical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova 1 2 4 0 2.43
Alliqua Biomedical 0 1 1 0 2.50

LivaNova currently has a consensus target price of $80.17, indicating a potential downside of 7.48%. Alliqua Biomedical has a consensus target price of $8.90, indicating a potential upside of 375.94%. Given Alliqua Biomedical’s stronger consensus rating and higher probable upside, analysts plainly believe Alliqua Biomedical is more favorable than LivaNova.

Institutional and Insider Ownership

85.5% of LivaNova shares are owned by institutional investors. Comparatively, 16.8% of Alliqua Biomedical shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Comparatively, 15.8% of Alliqua Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

LivaNova has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Alliqua Biomedical has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Valuation and Earnings

This table compares LivaNova and Alliqua Biomedical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LivaNova $1.01 billion 4.13 -$25.08 million ($0.54) -160.46
Alliqua Biomedical $19.56 million 0.48 -$25.70 million ($9.86) -0.19

LivaNova has higher revenue and earnings than Alliqua Biomedical. LivaNova is trading at a lower price-to-earnings ratio than Alliqua Biomedical, indicating that it is currently the more affordable of the two stocks.

Summary

LivaNova beats Alliqua Biomedical on 9 of the 13 factors compared between the two stocks.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers SilverSeal.

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply